Education
About Us
Working with TipRanks
Follow Us
Pharming Group (NL:PHARM)
:PHARM
PHARM Stock Chart & Stats
€1.40
-€0.03(-3.69%)
At close: 4:00 PM EST
€1.40
-€0.03(-3.69%)
Day’s Range― - ―
52-Week Range€0.66 - €1.53
Previous CloseN/A
Volume8.99M
Average Volume (3M)19.18M
Market Cap
€960.58M
Enterprise Value€633.89M
Total Cash (Recent Filing)€166.17M
Total Debt (Recent Filing)€130.92M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Mar 12, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding685,147,640
10 Day Avg. Volume15,825,784
30 Day Avg. Volume19,178,179
Financial Highlights & Ratios
PEG Ratio-2.95
Price to Book (P/B)2.98
Price to Sales (P/S)2.22
P/FCF Ratio-255.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Pharming Group News
PHARM FAQ
What was Pharming Group’s price range in the past 12 months?
Pharming Group lowest stock price was €0.66 and its highest was €1.53 in the past 12 months.
What is Pharming Group’s market cap?
Pharming Group’s market cap is €960.58M.
When is Pharming Group’s upcoming earnings report date?
Pharming Group’s upcoming earnings report date is Mar 12, 2026 which is in 79 days.
How were Pharming Group’s earnings last quarter?
Pharming Group released its earnings results on Nov 06, 2025. The company reported €0.009 earnings per share for the quarter, beating the consensus estimate of €0 by €0.009.
Is Pharming Group overvalued?
According to Wall Street analysts Pharming Group’s price is currently Overvalued.
Does Pharming Group pay dividends?
Pharming Group does not currently pay dividends.
What is Pharming Group’s EPS estimate?
Pharming Group’s EPS estimate is <0.01.
How many shares outstanding does Pharming Group have?
Pharming Group has 685,147,640 shares outstanding.
What happened to Pharming Group’s price movement after its last earnings report?
Pharming Group reported an EPS of €0.009 in its last earnings report, beating expectations of €0. Following the earnings report the stock price went up 24.251%.
Which hedge fund is a major shareholder of Pharming Group?
Currently, no hedge funds are holding shares in NL:PHARM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pharming Group
Pharming Group N.V. is a biopharmaceutical company focused on developing innovative therapies for rare diseases, particularly those affecting the complement system. Headquartered in the Netherlands, Pharming specializes in the development of recombinant proteins, with its core product being Ruconest, a treatment for acute attacks of Hereditary Angioedema (HAE). The company operates primarily in the biopharmaceutical sector, aiming to address unmet medical needs through its advanced protein-based therapies.
PHARM Company Deck
PHARM Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance with significant revenue growth and upgraded guidance. RUCONEST and Joenja both showed robust performance, and the company's cash position has been restored. However, there is a planned withdrawal of RUCONEST from certain markets due to financial sustainability concerns. Overall, the positive aspects significantly outweigh the lowlight.View all NL:PHARM earnings summariesTechnical Analysis
Options Prices
Currently, No data available
---